Th2 infiltration is a better predictor of survival than tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer (TNBC)

Susie Brousse, Florence Godey, Patrick Tas, Boris Campillo-Gimenez, Elodie Lafont, Amanda Poissonnier, Jean Levêque, Vincent Lavoué, Matthieu Le Gallo
doi: https://doi.org/10.1101/2023.06.02.23289891

Article Information

doi 
https://doi.org/10.1101/2023.06.02.23289891
History 
  • June 6, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Susie Brousse1,2,5,*,
  2. Florence Godey1,2,
  3. Patrick Tas2,3,
  4. Boris Campillo-Gimenez1,4,
  5. Elodie Lafont2,
  6. Amanda Poissonnier2,
  7. Jean Levêque2,5,
  8. Vincent Lavoué5 and
  9. Matthieu Le Gallo1,2,*
  1. 1Centre de lutte contre le cancer Eugène Marquis, Rennes, France
  2. 2Inserm UMR_S 1242, Chemistry Oncogenesis Stress Signaling, University of Rennes
  3. 3Department of Pathology, Rennes University Hospital, Rennes, France
  4. 4Inserm, LTSI - UMR 1099, F-35000 Rennes, France
  5. 5Department of Gynecology and Obstetrics, Rennes University Hospital, Rennes, France
  1. ↵*Correspondance to SB (s.brousse{at}rennes.unicancer.fr) and MLG (matthieu.legallo{at}univ-rennes.fr)
Back to top
Posted June 06, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Th2 infiltration is a better predictor of survival than tumor-infiltrating lymphocytes (TILs) in triple-negative breast cancer (TNBC)
Susie Brousse, Florence Godey, Patrick Tas, Boris Campillo-Gimenez, Elodie Lafont, Amanda Poissonnier, Jean Levêque, Vincent Lavoué, Matthieu Le Gallo
medRxiv 2023.06.02.23289891; doi: https://doi.org/10.1101/2023.06.02.23289891
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area